| Accession |
PRJCA023699 |
| Title |
A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer |
| Relevance |
Medical |
| Data types |
Genome sequencing
|
| Organisms |
Homo sapiens
|
| Description |
To compare PFS of patients with progressive, advanced, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib. |
| Sample scope |
Multiisolate |
| Release date |
2024-02-20 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Eli Lilly and Company
|
|
JXHL1900250/JXHL1900251
|
|
|
|
| Submitter |
Minghua
Hua
Ge (gemingh@163.com)
|
| Organization |
Zhejiang Provincial People's Hospital |
| Submission date |
2024-02-20 |
